home / stock / ktta / ktta news

KTTA News and Press, Pasithea Therapeutics Corp. From 11/28/25

Stock Information
Company Name: Pasithea Therapeutics Corp.
Stock Symbol: KTTA
Market: NASDAQ
Website: pasithea.com
Menu
KTTA KTTA Quote KTTA Short KTTA News KTTA Articles KTTA Message Board
Get KTTA Alerts

News, Short Squeeze, Breakout and More Instantly...
KTTA - US Companies Moving the Markets, Morning edition
Fri, Nov 28, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 8.1% to $3.63 on volume of 267,348,225 shares NVIDIA Corporation (NVDA) rose 1.4% to $180.26 on volume of 183,852,010 shares Beyond Meat Inc. (BYND) rose 19.0% to $1.02 on volume o...
KTTA - US Companies Moving the Markets, Evening edition
Wed, Nov 26, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 10.0% to $3.5564 on volume of 231,186,272 shares Beyond Meat Inc. (BYND) rose 17.9% to $1.0104 on volume of 153,212,982 shares NVIDIA Corporation (NVDA) rose 1.6% to $180.615 on vo...

KTTA - US Companies Moving the Markets, Morning edition
Tue, Nov 25, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 13.3% to $3.98 on volume of 361,797,467 shares Inno Holdings Inc. (INHD) fell 33.6% to $0.4811 on volume of 339,364,867 shares Inspire Veterinary Partners Inc. (IVP) rose 33.3% to ...

KTTA - Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomarker-driven clinical trials of novel or repurposed therapeutics for ALS -- MIAMI, Nov. 25, ...
KTTA - US Companies Moving the Markets, Evening edition
Mon, Nov 24, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 13.1% to $3.9901 on volume of 320,877,657 shares Inspire Veterinary Partners Inc. (IVP) rose 32.0% to $0.16 on volume of 291,282,700 shares Inno Holdings Inc. (INHD) fell 15.8% to ...

KTTA - US Companies Moving the Markets, Morning edition
Mon, Nov 24, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 2.8% to $4.59 on volume of 703,462,475 shares NVIDIA Corporation (NVDA) fell 1.0% to $178.88 on volume of 346,926,153 shares Inspire Veterinary Partners Inc. (IVP) fell 2.3% to $0....

KTTA - Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin ratio <2. Achieved exposures (AUC) of 6,690 ng·h/mL – -- Pharmac...
KTTA - US Companies Moving the Markets, Evening edition
Fri, Nov 21, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 5.6% to $4.455 on volume of 642,544,665 shares NVIDIA Corporation (NVDA) rose 0.4% to $181.345 on volume of 290,962,122 shares Nuvve Holding Corp. (NVVE) rose 45.4% to $0.23855 on ...

KTTA - Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability -- -- ...

KTTA - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

-- Evidence of Monotherapy Activity : Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved s...
Previous 10 Next 10